Oncology Clinical Trial Finder
Breast Cancer

Active, not recruiting • Phase I • Stage 0, I, II, III, IV • Post-Menopausal • Interventional

The following is imported from ClinicalTrials.gov:

[18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer

In this study, positron emission tomography (PET/CT) imaging will be used to evaluate sigma-2 (σ2) receptor activity in sites of primary breast cancer using the investigational radiotracer [18F]ISO-1.

This study will evaluate the feasibility of using [18F]ISO-1 PET/CT to image sigma-2 receptor binding in primary breast tumors and continue to evaluate the safety of the tracer in this patient population. [18F]ISO-1 uptake measures will be correlated with qualitative immunohistochemical staining for cell proliferation (Ki67). This is an observational study in that [18F]ISO-1 PET/CT will not be used to direct treatment decisions.

Breast Cancer

Study Design
Study type:


Estimated enrollment:

30 participant

Actual study start date:

November 20, 2014

Eligibility Criteria
Ages eligible for study:

18 - 999

Sexes eligible for study:


Arms and Intervention
  • [18F]ISO-1

Inclusion criteria
  • adult patients, at least 18 years of age

  • known or suspected breast cancer with at least one breast lesion that is 1 cm or greater in size by standard imaging (e.g. mammography, ultrasound or breast mri)

  • participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures

Exclusion criteria
  • females who are pregnant at the time of screening will not be eligible for this study, urine or serum pregnancy test will be performed in women of child-bearing potential at the time of screening.

  • inability to tolerate imaging procedure in the opinion of an investigator or treating physician

  • serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.

  • unwilling or unable to provide informed consent.

Trial Information at Site
Last Updated:
Trial Information
ClinicalTrial.gov ID:

Active, not recruiting

Estimated Enrollment:


Last Updated:


Principal Investigator

Elizabeth McDonald, MD, PhD

Trial Sponsor

University of Pennsylvania

Study Location (1)

University of Pennsylvania Hospital

Philadelphia, Pennsylvania, United States


© 2024 Outcomes4Me Inc. All rights reserved.